I-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline

I-MAB ( (IMAB) ) has issued an announcement.

On August 1, 2025, I-Mab announced the pricing of an underwritten offering of 33,333,334 American Depositary Shares (ADSs) at $1.95 per ADS, expected to raise approximately $65 million in gross proceeds. The offering, which is anticipated to close on August 5, 2025, will support the company’s ongoing clinical development, including a Phase 2 trial of givastomig, and general corporate purposes. This move is significant for I-Mab’s strategic positioning in the biotech industry, as it aims to advance its pipeline and strengthen its financial foundation.

The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

Spark’s Take on IMAB Stock

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

More about I-MAB

I-Mab is a U.S.-based, global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company’s pipeline is led by givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers, with potential applications in other solid tumors.

Average Trading Volume: 1,302,323

Technical Sentiment Signal: Buy

Current Market Cap: $206.8M

For an in-depth examination of IMAB stock, go to TipRanks’ Overview page.